Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to $55.6 million.

  • Foghorn Therapeutics' Shares Outstanding (Weighted Average) rose 2.17% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 2.17%. This contributed to the annual value of $55.6 million for FY2024, which is 31.68% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Shares Outstanding (Weighted Average) of $55.6 million as of FY2024, which was up 31.68% from $42.2 million recorded in FY2023.
  • Over the past 5 years, Foghorn Therapeutics' Shares Outstanding (Weighted Average) peaked at $55.6 million during FY2024, and registered a low of $35.8 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $42.2 million (2023), whereas its average is $46.5 million.
  • Data for Foghorn Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 31.68% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Shares Outstanding (Weighted Average) stood at $35.8 million in 2020, then increased by 3.57% to $37.1 million in 2021, then increased by 12.70% to $41.8 million in 2022, then rose by 0.99% to $42.2 million in 2023, then soared by 31.68% to $55.6 million in 2024.